Posts Tagged ‘glioblastoma’
Background: There is evidence in the literature that supports fluorescent tissue signal in fluorescence guided surgery (FGS) extends farther than tissue highlighted in T1Gd MRI, which is the standard to quantify the extent of resection (EOR).
Objective: To study whether the presence of residual fluorescent tissue after surgery carries a different prognosis for glioblastoma (GBM) cases with complete resection confirmed by MRI.
Methods: A retrospective review in our center found 118 consecutive patients with high-grade gliomas operated using 5-aminolevulinic acid (5-ALA) FGS. Within that series, the 52 patients with newly diagnosed GBM and complete resection of enhancing tumor (CRET) in early MRI were selected for analysis. We studied the influence of residual fluorescence in the surgical field on overall survival and neurological complication rate. Multivariate analysis included potential relevant factors: age, Karnofsky Performance Scale (KPS), MGMT methylation promoter status, tumor eloquent location, preoperative tumor volume, and adjuvant therapy.
Background: xCT is a light chain of the cystine/glutamate antiporter system xc-. Glutamate that is released by system xc- plays an important role in the infiltration of glioblastoma (GBM) cells. Furthermore, increased glutathione synthesis by system xc- may protect tumor cells from oxidative stress induced by radiotherapy and chemotherapy.
Objective: To investigate whether the levels of xCT expression correlated with infiltrative imaging phenotypes on magnetic resonance imaging (MRI) and outcomes in patients with GBMs.
Methods: Forty patients with histologically confirmed primary GBM were included in the present study. Patient charts were retrospectively reviewed for age, sex, Karnofsky performance status (KPS), mini-mental state examination scores, MRI features, xCT expression, isocitrate dehydrogenase 1 (IDH1) R132H expression, O6-methylguanine-DNA methyltransferase promoter methylation status, type of surgery, progression-free survival (PFS), and overall survival (OS).
Ahead of Print: Neurosurgical Management and Prognosis of Patients with Glioblastoma that Progress During Bevacizumab Treatment
BACKGROUND: The management and prognosis of glioblastoma patients after Stupp protocol treatment and progression during bevacizumab (BV) treatment remains undefined.
OBJECTIVE: We compared the morbidity and survival of patients whose glioblastomas progressed during bevacizumab treatment requiring craniotomy to non-bevacizumab-treated patients.
METHODS: We retrospectively reviewed patients who underwent craniotomy for recurrent glioblastoma from 2005-2009. Patients operated on for progression during bevacizumab (preoperative bevacizumab) were compared to patients receiving no bevacizumab or bevacizumab after surgery (postoperative bevacizumab). Preoperative bevacizumab patients were compared to those progressing on bevacizumab but not operated on (no surgery).